The Cancer-Associated Lipid Paradox: Implications for Cardiovascular Risk and Lipid Management.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic and clinical concepts without original human data or systematic review methodology.
PubMed 42628824 · doi:10.1016/j.amjcard.2026.08.022
What was done
This narrative review synthesized mechanistic, angiographic, and clinical evidence evaluating cardiovascular risk assessment in oncology patients, specifically examining the decoupling of low-density lipoprotein cholesterol (LDL-C) from atherosclerotic risk and evaluating lipid management strategies in cardio-oncology.
What was found
The abstract reports no numerical findings, sample sizes, or effect estimates. It outlines the cancer-associated lipid paradox, wherein atherosclerotic events occur frequently despite low or controlled LDL-C levels due to systemic inflammation, hypercoagulability, tumor metabolic reprogramming, cachexia, and vascular injury caused by treatments including anthracyclines, immune checkpoint inhibitors, HER2-targeted agents, androgen-deprivation therapy, and thoracic radiation. Lipoprotein(a) is also highlighted as a contributor to risk not captured on standard lipid panels.
Why it matters
Conventional LDL-C-centric risk models may systematically underestimate cardiovascular risk in cancer patients. A precision cardio-oncology framework focusing on dynamic, longitudinal risk assessment is proposed to improve prevention in cancer survivors.
Limits
The publication is a narrative review without primary empirical data, systematic literature search methodology, or quantitative synthesis. The abstract provides no quantitative thresholds, risk estimates, or clinical trial outcomes.
Cited by
- supports Low LDL cholesterol levels in cancer patients are associated with faster cancer progression.